Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Danaher to Sell Some Businesses to Sartorius for $750 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/21/2019 | 06:22am EST

By Colin Kellaher

Danaher on Monday said it agreed to sell some businesses of its life-science segment to Germany's Sartorius for about $750 million in a bid to gain regulatory approval for its $21 billion acquisition of General Electric Co.'s (GE) GE Biopharma unit.

The Washington science and technology company said the sale includes its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses, which had combined revenue of roughly $140 million in 2018.

Danaher said the timing around meeting all closing conditions, including regulatory approvals, for the GE Biopharma deal remains uncertain, but said it expects to complete the acquisition in the first quarter of 2020.

Sartorius said the planned acquisition complements its positions in two fast-growing bioanalytics and bioprocessing segments.

Shares of Sartorius rose 4.7% to EUR156.50 on Monday.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BIO-RAD LABORATORIES, INC. 1.63% 364.12 Delayed Quote.56.80%
DANAHER CORPORATION 2.40% 143.6 Delayed Quote.35.99%
GENERAL ELECTRIC COMPANY 0.52% 11.5 Delayed Quote.51.92%
SARTORIUS -0.61% 163 Delayed Quote.70.83%
SARTORIUS STEDIM BIOTECH -0.07% 135.3 Real-time Quote.55.01%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DANAHER CORPORATION
11/18Qiagen shares surge as diagnostics group says open to takeover talks
RE
11/18DANAHER : Will Commence Exchange Offer Related To Divestiture of Its Remaining I..
AQ
11/15DANAHER : Sets Exchange Offer as It Works to Shed Remaining Envista Stake
DJ
11/14DANAHER : Announces Appointment of Jessica L. Mega, MD, MPH and Pardis C. Sabeti..
AQ
11/07DANAHER CORP /DE/ : Entry into a Material Definitive Agreement, Financial Statem..
AQ
10/31DANAHER CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/31GE Posts Loss but Raises Cash Outlook -- WSJ
DJ
10/29DANAHER : Announces Pricing Of Senior Notes Offering
PR
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/28DANAHER : To Present At Baird Global Industrial Conference
PR
More news
Financials (USD)
Sales 2019 20 610 M
EBIT 2019 3 611 M
Net income 2019 2 634 M
Debt 2019 1 009 M
Yield 2019 0,47%
P/E ratio 2019 39,7x
P/E ratio 2020 33,9x
EV / Sales2019 5,05x
EV / Sales2020 5,09x
Capitalization 103 B
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 151,50  $
Last Close Price 143,60  $
Spread / Highest target 21,2%
Spread / Average Target 5,50%
Spread / Lowest Target -16,4%
EPS Revisions
Managers
NameTitle
Thomas Patrick Joyce President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer
Alan G. Spoon Independent Director
Donald Jerry Ehrlich Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER CORPORATION35.99%103 145
THERMO FISHER SCIENTIFIC34.50%120 694
INTUITIVE SURGICAL, INC.20.65%65 772
BOSTON SCIENTIFIC CORPORATION20.63%58 945
EDWARDS LIFESCIENCES CORPORATION59.01%50 553
SIEMENS HEALTHINEERS18.77%48 157